Anemia is a major complication in dialysis patients which was associated with poor clinical outcomes such as reduced quality of life, risk of cardiovascular disease, cognitive impairment, and mortality.[1] Since the introduction of recombinant human erythropoietin (EPO) in 1990s, the prognosis for anemia in renal failure has improved drastically. Here, EPO is linked to acute kidney injury.